Concepedia

Michael R. Migden

MR

Statistics

Publications

50

Citations

7.2K

H-Index

29

Active since

1996

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Stanford University

University of Colorado Denver

Moffitt Cancer Center

Royal North Shore Hospital

Michael R. Migden is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer pharmacology.

ORCID

Publications per year

1996–2025

50

Publications

50

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro et al. · New England Journal of Medicine · 2012 · 1.4K citations · Full text

, , +17

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

, , +17

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang et al. · The Lancet Oncology · 2020 · 480 citations · Full text

, , +13

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

Michael R. Migden, Alexander Guminski, Ralf Gutzmer et al. · The Lancet Oncology · 2015 · 429 citations

, , +7

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Aleksandar Sekulić, Michael R. Migden, Nicole Basset‐Séguin et al. · BMC Cancer · 2017 · 412 citations · Full text

, , +14

1–5 of 50